Sponsors

IARC’s Mission: Cancer research for cancer prevention The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions. Causes and prevention of cancer Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies. A global reference for cancer information The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN. The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience. Global cancer biobank One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners. Education and training A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration. Producing evidence-based science for global cancer control policies The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals.

TBA

The Dutch Cancer Society is a nation-wide organization for cancer control in the Netherlands. The society was funded in 1949 by Queen Wilhelmina. Her granddaughter, Her Royal Highness Princess Beatrix, is the current patron. The Dutch Cancer Society’s ideal world is one in which nobody dies from cancer ever again. We want fewer people to get cancer, more people to cure, and patients to have a better quality of life, during and after the disease. That’s why we fund and facilitate scientific research, influence policy, and share our knowledge about cancer and its treatment. To make this possible, we raise funds and establish links with other parties involved in cancer control, both here in the Netherlands and elsewhere. The Dutch Cancer Society is entirely dependent on community involvement and donations. Over 100.000 volunteers support the Dutch Cancer Society whether it comes to local or nation-wide fundraising, scientific or policy advice in several councils and committees. We can rely on nearly 1.500 local committees that organize fundraising activities e.g. our annual door-to-door campaign to raise funds for the fight against cancer. The Dutch Cancer Society is supported by over 1 million donors. The Dutch Cancer Society’s office is located in Amsterdam; our professional staff amounts to 198 staff members. The Dutch Cancer Society became full UICC member in 1982

Created in 2000, Gavi is an international organisation – a global Vaccine Alliance, bringing together public and private sectors with the shared goal of saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.

More info to be added soon

More info to be added soon.

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.

Becton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

The Chinese Anti-Cancer Association (CACA), founded in 1984, has a mission to unite people involved in all branches of oncology and others with a similar interest in fighting cancer. CACA aims its utmost efforts at organizing scientific cooperation and conferences, promoting international non-governmental exchanges, conducting various training courses and seminars, fostering scientific, technological and medical personnel in the field of oncology, compiling and publishing academic periodicals, and mobilizing social forces to take part in popularization and dissemination of the knowledge of tumor prevention. Globally, the association is interested in organizing academic meetings with international colleagues in order to cultivate friendly ties with overseas oncology organizations and individuals. The Chinese Anti-Cancer Association has been a full UICC member since January 1997.

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations with nearly 45,000 members in over 150 countries. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

Healio enables you, the health care specialist, to select and tailor news and education to fit your daily practice of medicine. Designed as an in-depth specialty clinical information website, Healio features the industry’s best news reporting, dynamic multimedia, podcasts, question-and-answer columns, CME and other educational activities in a variety of formats, quick reference content, blogs, peer-reviewed journals and a wide range of popular medical book titles.

The Medicaid Cancer Foundation (MCF) is a vehicle created by Medicaid to support cancer patients, promote cancer awareness and drive community cancer campaigns for undeserved populace in Nigeria. We provide support to guide people through the cancer experience, bring them together to fight cancer—and work for a world in which our fight is no longer necessary

On October 12, 1968, the Nigerian Cancer Society (NCS) was founded with the objective to assist in the development of facilities for diagnosis and treatment of cancer, to educate the public on ther problems of cancer, and to conduct research in all aspects of cancer. Since its founding, the society has expanded beyond the original founding town of Ibadan, and branches now exist in six geo-political zones of Nigeria. NCS’ first major successful publication was in 1982 with the book “Cancer in Nigeria-the proceedings of the NCS conference held in December 1979.” Since 1970, Nigerian Cancer Society has been associate UICC member.

Our organization is focused on young women concerned about and affected by breast cancer. We educate young women about risk factors and how to be breast aware and "risk savvy" by organizing public heath forums, making documentary films and short videos, writing blog posts and engaging young people in the breast health conversation on social media. In addition, we are involved in trying to improve the experience for young women who find themselves diagnosed with breast cancer. We connect young women with breast cancer and create a community for them; we listen to their needs to identify gaps in care and then inspire them to work together and with us to create resources to address the unique needs of younger breast cancer patients and make changes to our health care system to improve the lives of other young women. We advocate for improved access to new innovative treatments in Canada. We want to make sure a young woman gets the right treatment at the ri

The Lancet Oncology is the world-leading journal dedicated to clinical oncology research, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology. As an internationally trusted source of clinical, public health, and global health knowledge, with an Impact Factor of 54.433 (2021 Journal Citation Reports®, Clarivate 2022), we have also fostered a reputation for hosting events for oncologists, cancer researchers, and policymakers, and convene many conferences, either independently or in collaboration with partners. Events include branded plenary lectures and sessions at conferences worldwide. We publish a range of article types that encompass all aspects of oncological medicine: Articles, Review, Policy Review, Personal View, Clinical Picture, Comment, Correspondence, News, and Perspectives. As part of our flagship advocacy programme, we also publish Series and Commissions (typically in partnership with societies, governments, NGOs, and academic centres) that aim to shape and drive positive change in clinical practice and health policy in areas of need in global oncology.